Focus Surgery Seeks IDE For Sonablate HIFU Prostate Cancer Treatment
This article was originally published in The Gray Sheet
Executive Summary
Focus Surgery says it will file an investigational device exemption application with FDA in mid-to-late 1999 to begin U.S. clinical trials of the Sonablate 200 high-intensity focused ultrasound (HIFU) system for treatment of prostate cancer.
You may also be interested in...
Misonix Sonablate PMA Submission For BPH Expected In September
Misonix is looking toward a late September premarket approval application filing date for the Sonablate 200 high intensity focused ultrasound (HIFU) device in treating benign prostatic hyperplasia. Commercial release of the product in the U.S. is expected sometime in 2001.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.